速释型溴隐亭治疗2型糖尿病患者有效性的系统评价
摘要
系统评价速释型溴隐亭用于治疗2型糖尿病患者的有效性,以期为其在临床上的使用提供循证参考。采用计算机检索CENTRAL、Pub Med,Medline、Embase、中国知网、维普数据库和万方数据库,收集速释型溴隐亭或速释型溴隐亭合并其他降糖药物治疗2型糖尿病的的随机对照试验(RCT),提取资料并进行质量评价后,采用Rev Man 5.3统计软件进行Meta分析。最终纳入9篇RCT,合计9309例患者。Meta分析显示:速释型溴隐亭组患者经治疗,糖化血红蛋白较安慰剂组下降更明显,空腹血糖较安慰剂组下降更明显,餐后血糖较安慰剂组下降不明显。速释型溴隐亭并未增加患者心血管疾病的风险。速释型溴隐亭对2型糖尿病患者的降糖效果明显,由于国内该药并未批准治疗2型糖尿病的适应症,临床上使用仍需谨慎。
引文
[1]中华医学会糖尿病学分会.中国型糖尿病防治指南年版[J].中国糖尿病杂志,2014,22(8):2-42.
[2]Defronzo RA.Bromocriptine:A sympatholytic,d2-dopamine agonist for the treatment of type diabetes[J].Diabetes Care,2011,34(4):789-794.
[3]Kerr JL,Timpe EM,Petkewicz KA.Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus[J].Ann Pharmacother,2010,44(11):1777-1785.
[4]American Diabetes Association.Standards of medical care in diabetes-2015[J].Diabetes Care,2015,38(Suppl 1):S1-S92.
[5]Higgins JPT,Altman DG.Chapter 8:Assessing risk of bias in included studies.In:Higgins JPT,Green S(editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0(updated March 2011)[M].The Cochrane Collaboration,2011,Available from www.cochrane-handbook.org.
[6]Higgins JPT,Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0[updated February 2008][M].The Cochrane Collaboration,2008.
[7]Higgins JPT,Thompson SG.Quantifying heterogeneity in a Meta-analysis[J].Statist Med,2002,21(11):1539-1558.
[8]Chamarthi B,Gaziano JM,Blonde L,et al.Timed BromocriptineQR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus[J].J Diabetes Res,2015:157698.
[9]Ghosh A,Sengupta N,Sahana P,et al.Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus:A randomized open labeled phase IV clinical trial[J].Indian J Pharmacol,2014,46(1):24-28.
[10]Vinik AI,Cincotta AH,Scranton RE,et al.Effect of bromocriptineQR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents[J].Endocr Pract,2012,18(6):931-943.
[11]Gaziano JM,Cincotta AH,Vinik A,et al.Effect of bromocriptineQR(a quick-release formulation of bromocriptine mesylate)on major adverse cardiovascular events in type 2 diabetes subjects[J].J Am Heart Assoc,2012,1(5):e002279.
[12]Ramteke KB,Ramanand SJ,Ramanand JB,et al.Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes[J].Indian J Endocrinol Metab,2011,15(Suppl 1):S33-39.
[13]Gaziano JM,Cincotta AH,O'Connor CM,et al.Randomized clinical trial of quick-release bromocriptine among patients with type2 diabetes on overall safety and cardiovascular outcomes[J].Diabetes Care,2010,33(7):1503-1508.
[14]Aminorroaya A,Janghorbani M,Ramezani M,et al.Does bromocriptine improve glycemic control of obese type-2 diabetics[J].Horm Res,2004,62(2):55-59.
[15]Pijl H,Ohashi S,Matsuda M,et al.Bromocriptine:A novel approach to the treatment of type 2 diabetes[J].Diabetes Care,2000,23(8):1154-1161.
[16]Cincotta AH,Meier AH,Cincotta Jr M.Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects:A new approach in the treatment of diabetes[J].Expert Opin Investig Drugs,1999,8(10):1683-1707.
[2]Defronzo RA.Bromocriptine:A sympatholytic,d2-dopamine agonist for the treatment of type diabetes[J].Diabetes Care,2011,34(4):789-794.
[3]Kerr JL,Timpe EM,Petkewicz KA.Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus[J].Ann Pharmacother,2010,44(11):1777-1785.
[4]American Diabetes Association.Standards of medical care in diabetes-2015[J].Diabetes Care,2015,38(Suppl 1):S1-S92.
[5]Higgins JPT,Altman DG.Chapter 8:Assessing risk of bias in included studies.In:Higgins JPT,Green S(editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0(updated March 2011)[M].The Cochrane Collaboration,2011,Available from www.cochrane-handbook.org.
[6]Higgins JPT,Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0[updated February 2008][M].The Cochrane Collaboration,2008.
[7]Higgins JPT,Thompson SG.Quantifying heterogeneity in a Meta-analysis[J].Statist Med,2002,21(11):1539-1558.
[8]Chamarthi B,Gaziano JM,Blonde L,et al.Timed BromocriptineQR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus[J].J Diabetes Res,2015:157698.
[9]Ghosh A,Sengupta N,Sahana P,et al.Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus:A randomized open labeled phase IV clinical trial[J].Indian J Pharmacol,2014,46(1):24-28.
[10]Vinik AI,Cincotta AH,Scranton RE,et al.Effect of bromocriptineQR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents[J].Endocr Pract,2012,18(6):931-943.
[11]Gaziano JM,Cincotta AH,Vinik A,et al.Effect of bromocriptineQR(a quick-release formulation of bromocriptine mesylate)on major adverse cardiovascular events in type 2 diabetes subjects[J].J Am Heart Assoc,2012,1(5):e002279.
[12]Ramteke KB,Ramanand SJ,Ramanand JB,et al.Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes[J].Indian J Endocrinol Metab,2011,15(Suppl 1):S33-39.
[13]Gaziano JM,Cincotta AH,O'Connor CM,et al.Randomized clinical trial of quick-release bromocriptine among patients with type2 diabetes on overall safety and cardiovascular outcomes[J].Diabetes Care,2010,33(7):1503-1508.
[14]Aminorroaya A,Janghorbani M,Ramezani M,et al.Does bromocriptine improve glycemic control of obese type-2 diabetics[J].Horm Res,2004,62(2):55-59.
[15]Pijl H,Ohashi S,Matsuda M,et al.Bromocriptine:A novel approach to the treatment of type 2 diabetes[J].Diabetes Care,2000,23(8):1154-1161.
[16]Cincotta AH,Meier AH,Cincotta Jr M.Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects:A new approach in the treatment of diabetes[J].Expert Opin Investig Drugs,1999,8(10):1683-1707.